Rovalpituzumab tesirine (Rova-T) is an experimental antibody-drug conjugate targeting the protein DLL3 on tumor cells. It was originally developed by...
6 KB (404 words) - 01:44, 29 November 2023
a possible treatment for lung cancer including Tarlatamab and rovalpituzumab tesirine. GRCh38: Ensembl release 89: ENSG00000090932 – Ensembl, May 2017...
7 KB (879 words) - 23:24, 26 February 2024
Rosmantuzumab mab humanized root plate-specific spondin 3 cancer Rovalpituzumab tesirine mab humanized DLL3 small cell lung cancer Rovelizumab LeukArrest...
136 KB (4,020 words) - 07:14, 15 August 2024
Pertuzumab Pinatuzumab vedotin§ Polatuzumab vedotin Rosmantuzumab Rovalpituzumab tesirine† Sacituzumab govitecan Sibrotuzumab§ Simtuzumab§ Sofituzumab vedotin§...
4 KB (241 words) - 13:42, 14 July 2024
Pertuzumab Pinatuzumab vedotin§ Polatuzumab vedotin Rosmantuzumab Rovalpituzumab tesirine† Sacituzumab govitecan Sibrotuzumab§ Simtuzumab§ Sofituzumab vedotin§...
5 KB (368 words) - 15:29, 21 August 2024
Pertuzumab Pinatuzumab vedotin§ Polatuzumab vedotin Rosmantuzumab Rovalpituzumab tesirine† Sacituzumab govitecan Sibrotuzumab§ Simtuzumab§ Sofituzumab vedotin§...
3 KB (129 words) - 01:04, 19 July 2023